BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies

Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Combination With Full Dose Erbitux in Patients With Advanced Gastrointestinal Malignancies Who Have Failed Prior Therapy

This is a phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in combination with full dose erbitux in patients with advanced colorectal cancer who have received no more than 2 prior regimens for metastatic colorectal cancer.

Inclusion Criteria:

• Diagnosis of advanced or metastatic (tumor has spread) gastrointestinal malignancy
• Feeling well other than cancer diagnosis (ie lab work, no infection, etc)
• Available tumor tissue sample from prior surgery
• Measurable disease on scans
• 4-6 weeks since prior therapy and recovered from the effects of prior therapy
• Men and women, ages 18 and above
• Women must not be pregnant or breastfeeding